CRC Research Update — September 19, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Saturday, September 19, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
RESEARCH
Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancerA narrative review summarizes evidence that the gut microbiome-immune axis regulates antitumor immunity and may mediate both primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR CRC. (Front Cell Infect Microbiol)
-
LIVING WITH CRC
Study assesses impact of concurrent palliative care on metastatic CRC patients on systemic therapyA retrospective study of 201 metastatic CRC patients assessed the impact of concurrent multidisciplinary palliative care alongside systemic therapy on patient-reported outcomes and healthcare utilization. (Front Oncol)
-
SCREENING
Newer colonoscope models and texture enhancement imaging improve adenoma detectionAnalysis of 28,459 colonoscopies aimed to identify clinical and technological factors most strongly associated with increased adenoma detection rate, including newer colonoscope models and texture and color enhancement imaging. (Scand J Gastroenterol)
-
RESEARCH
Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapyA retrospective cohort study of 221 metastatic CRC patients receiving anti-PD-1/PD-L1 immunotherapy plus chemotherapy assessed tumor mutational burden as a biomarker for survival and quality of life outcomes. (Medicine)
Today's research spans microbiome mechanisms, supportive care integration, and screening technology advances.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data